soul trial oral semaglutide cardiovascular outcomes trial (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Abstract 4351008: Comparing Cardiovascular Outcomes
Pay in 4 interest-free payments of $6.24 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29









![Ozempic Thyroid Cancer Lawsuit [2026 Update]](https://trulaw.com/wp-content/uploads/2024/06/Eligibility-for-Filing-an-Ozempic-Thyroid-Cancer-Lawsuit-1.webp)













